Previous close | 5,680.85 |
Open | 0.00 |
Bid | 4,600.00 x 1300 |
Ask | 6,500.00 x 100000 |
Day's range | 5,680.85 - 5,680.85 |
52-week range | 3,800.00 - 5,680.85 |
Volume | |
Avg. volume | 96 |
Market cap | 3.047T |
Beta (5Y monthly) | 0.60 |
PE ratio (TTM) | 44.64 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 161.04 (2.83%) |
Ex-dividend date | 16 May 2024 |
1y target est | N/A |
Amgen (NASDAQ:AMGN) today announced the U.S. Food and Drug Administration (FDA) has approved BLINCYTO® (blinatumomab) for the treatment of adult and pediatric patients one month or older with CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia (B-ALL) in the consolidation phase, regardless of measurable residual disease (MRD) status.
Amgen (NASDAQ:AMGN) today announced the presentation of data across its diverse portfolio and pipeline at the European Alliance of Associations for Rheumatology's (EULAR) 2024 Congress, June 12-15 in Vienna. The 27 abstracts from Amgen-sponsored and partner-led studies demonstrate Amgen's commitment to improving the lives of patients living with inflammatory and rheumatic disease through the development of novel medicines.
Amgen (NASDAQ:AMGN) will present at the Goldman Sachs 45th Annual Global Healthcare Conference at 9:20 a.m. ET on Monday, June 10, 2024. Peter Griffith, executive vice president and chief financial officer at Amgen, and Jay Bradner, executive vice president of Research and Development and chief scientific officer at Amgen, will present at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general pu